Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum

Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum is organized by Clinical Care Options (CCO), LLC.,Released: January 17, 2023,Expiration: January 16, 2024,Goal:,The goal of this program is to improve the knowledge and competence of learners in integrating immunotherapies into treatment plans for patients with NSCLC.,Learning Objectives:,• Select optimal immune checkpoint inhibitor–based therapy for appropriate patients with NSCLC in the adjuvant and neoadjuvant settings, considering PD-L1 expression and expert recommendations,• Evaluate the impact of immune checkpoint inhibitor treatment in the neoadjuvant and adjuvant settings on agent sequencing and treatment decisions for patients with advanced or metastatic NSCLC,• Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy,• Incorporate investigational checkpoint inhibitors and clinical trial participation as part of therapeutic strategies for all eligible patients with NSCLC, considering known racial-related and age-related disparities in care,• Address factors that can influence response to immune checkpoint inhibitor therapy in individual patients with NSCLC,Additional details will be posted as soon as information is available.